Effects of dasatinib and conventional MM therapeutics on proliferation of plasma cell/EC growth. Dose-dependent inhibition of proliferation of MM plasma cells bound to ECs (A) or isolated MM patient ECs (MMECs) (B) cultured in absence (−) or in the presence of 5 nM dasatinib (+) and/or the indicated doses of bortezomib, thalidomide, melphalan, and prednisone for 48 hours. Data from a MMT-based cell viability assay were expressed as percentage of growth inhibition.